Key facts
- Solid IO’s last known valuation is $3.3M (Feb 2025).
- It has raised $830K; the latest was Grant ($9.3M) in Sep 2025.
- Notable investors include European Union, Business Finland, BSV Ventures, Health Incubator Helsinki, Nordic Science Investments — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Solid IO
- ·The full record, as it builds
Funding rounds
No funding rounds for Solid IO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solid IO
Developer of organ-on-chip technology designed to serve oncology research, pharmaceutical companies, and cancer clinics. The company replicates the tumor microenvironment to provide real-time insights into therapy responses, enabling doctors to make precise treatment decisions and accelerating immuno-oncology drug development.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Employees
- 5
- Website
- solid-io.com/
- Ownership
- Privately Held (backing)
Solid IO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solid IO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solid IO in its N-PORT filings yet. We sweep new filings monthly.